[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344860-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-344860-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","secondary-neoplasm-in-survivors-of-childhood-hematological-malignancies-systematic-review","Secondary Neoplasm in Survivors of Childhood Hematological Malignancies - Systematic Review","","Childhood cancers account for about 1–2% of malignancies worldwide, and hematologic cancers comprise roughly 35–40% of pediatric cases. With improved survival, therapy-related late effects have gained increasing attention, particularly secondary malignant neoplasms (SMNs), which remain among the most severe long-term complications. Using a PRISMA 2020–aligned systematic review of cohort and registry studies, the review evaluates SMN risk after childhood hematologic malignancies. Forty-three studies (>70,000 survivors) show standardized incidence ratios of 2.0–6.0 and absolute excess risks of ~10–40 per 10,000 person-years.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/secondary-neoplasm-in-survivors-of-childhood-hematological-malignancies-systematic-review/344860/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/secondary-neoplasm-in-survivors-of-childhood-hematological-malignancies-systematic-review/344860.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are secondary malignant neoplasms a key concern for childhood hematologic cancer survivors?","Question",{"text":63,"@type":64},"SMNs are among the most severe late effects of therapy. Survivors face a lifelong risk, with increased recognition driven by improved survival and longer follow-up.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the systematic review conducted?",{"text":68,"@type":64},"A PRISMA 2020–aligned systematic review was performed using cohort and registry studies. Databases included PubMed, Embase, Web of Science, Scopus, and Cochrane Library, with study selection and data extraction by two reviewers and bias assessment using the Newcastle–Ottawa Scale.",{"name":70,"@type":61,"acceptedAnswer":71},"What timing patterns and risk factors were reported for developing SMNs?",{"text":72,"@type":64},"Therapy-related acute myeloid leukemia occurred within 5–10 years, while solid SMNs emerged after 10–25 years. Higher risks were noted for female Hodgkin lymphoma survivors receiving chest and neck radiotherapy and for hematopoietic stem cell transplant recipients exposed to total body irradiation or chronic graft-versus-host disease.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},344860,1790097314,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":128,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Systematic Review  \nSecondary Neoplasm in Survivors of Childhood Hematological Malignancies—Systematic Review  \nIoana-Alexandra Hornet, 1, Andreea Bianca Stoica 2,*, Dora Mihaela Cîmpian 3 and Lucian Pu¸sca¸siu 1,4  \nAcademic Editor: John B. Amodio  \nReceived: 17 December 2025  \nRevised: 23 January 2026  \nAccepted: 28 January 2026  \nPublished: 31 January 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Doctoral School of Medicine, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mures,, Gheorghe Marinescu Street No. 38, 540136 Târgu Mures,, Romania; [alexandra.hornet@gmail.com](alexandra.hornet@gmail.com) (I.-A.H.); [puscasiu@gmail.com](puscasiu@gmail.com) (L.P.)  \n2 Department of Pediatrics 1, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mures,, Gheorghe Marinescu Street No 38, 540136 Târgu Mure¸s, Romania  \n3 Department of Ethics and Social Sciences, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mures,, 540139 Târgu Mure¸s, Romania; [dora.cimpian@umfst.ro](dora.cimpian@umfst.ro)  \n4 Department of Obstetrics and Gynecology 1, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mures,, Gheorghe Marinescu Street No. 38, 540136 Târgu Mures,, Romania  \n* Correspondence: [andreeabstoica9@gmail.com](andreeabstoica9@gmail.com)  \nAbstract  \nBackground: Childhood cancers account for approximately 1–2% of all malignancies worldwide, with hematologic cancers representing about 35–40% of pediatric cases. Improved survival has brought increased recognition of both acute and long-term therapy-related complications, including secondary malignant neoplasms (SMNs) . Survivors of pediatric hematologic malignancies face a lifelong risk of secondary malignant neoplasms (SMNs), which remain among the most severe late effects of therapy. Methods: We conducted a PRISMA 2020–aligned systematic review of cohort and registry studies evaluating SMNs after childhood hematologic cancers. Databases searched included PubMed, Embase, Web of Science, Scopus, and Cochrane Library. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the Newcastle–Ottawa Scale; disagreements were resolved by a third reviewer. Results: Forty-three studies (>70,000 survivors, median follow-up 5–30+ years) were included. Standardized incidence ratios (SIRs) for secondary malignant neoplasms compared to the general population ranged from 2.0 to 6.0, with absolute excess risks (AERs) of approximately 10–40 per 10,000 person-years. Therapy-related acute myeloid leukemia occurred within 5–10 years, while solid secondary malignant neoplasms (breast, thyroid, central nervous system, sarcomas) emerged after 10– 25 years. The highest risks for developing secondary malignant neoplasms were observed among female survivors of Hodgkin lymphoma treated with chest and neck radiotherapy, particularly during adolescence, and among hematopoietic stem cell transplant recipients exposed to total body irradiation or chronic graft-versus-host disease. Conclusions: SMNs are predictable late effects requiring lifelong, exposure-anchored surveillance. Precision survivorship—integrating treatment exposures, transplant conditioning, and genetic predisposition—should guide future screening strategies.  \nKeywords: childhood cancer survivors; hematologic malignancies; secondary malignant neoplasms; Hodgkin lymphoma; acute lymphoblastic leukemia; hematopoietic stem cell transplantation; radiotherapy; survivorship; PRISMA priorities for research and policy  \n1. Introduction  \nPediatric cancers are among the leading causes of disease-related death in children and adolescents, despite their relatively low incidence compared to adult cancers. Recent analyses indica","cbCairu9ktyaEveW","https://ap.wps.com/l/cbCairu9ktyaEveW","pdf",1477196,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"Why are secondary malignant neoplasms a key concern for childhood hematologic cancer survivors?\",\"answer\":\"SMNs are among the most severe late effects of therapy. Survivors face a lifelong risk, with increased recognition driven by improved survival and longer follow-up.\"},{\"question\":\"How was the systematic review conducted?\",\"answer\":\"A PRISMA 2020–aligned systematic review was performed using cohort and registry studies. Databases included PubMed, Embase, Web of Science, Scopus, and Cochrane Library, with study selection and data extraction by two reviewers and bias assessment using the Newcastle–Ottawa Scale.\"},{\"question\":\"What timing patterns and risk factors were reported for developing SMNs?\",\"answer\":\"Therapy-related acute myeloid leukemia occurred within 5–10 years, while solid SMNs emerged after 10–25 years. Higher risks were noted for female Hodgkin lymphoma survivors receiving chest and neck radiotherapy and for hematopoietic stem cell transplant recipients exposed to total body irradiation or chronic graft-versus-host disease.\"}]","Secondary Neoplasm in Survivors of Childhood Hematological Malignancies - Systematic Review | PDF",1790055479,48,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ee9156d2e229923f85ecd40c3ef7703.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5333f8b486803e46594a912b46e565c7.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/272a28e5cda50a7c1999d44257c6c511.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59528a087c34ad880a8d19bd2617864b.webp",980,1385]